AMIX - Autonomix Medical, Inc.


2.53
0.190   7.510%

Share volume: 674,757
Last Updated: 04-29-2025
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies: 0.00%

PREVIOUS CLOSE
CHG
CHG%

$2.34
0.19
0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
40%
Profitability 35%
Dept financing 31%
Liquidity 50%
Performance 45%
Company vs Stock growth
vs
Performance
5 Days
21.63%
1 Month
44.57%
3 Months
-17.05%
6 Months
-75.29%
1 Year
-21.67%
2 Year
-50.10%
Key data
Stock price
$2.53
P/E Ratio 
0.00
DAY RANGE
$2.23 - $2.82
EPS 
-$12.85
52 WEEK RANGE
$0.46 - $21.49
52 WEEK CHANGE
-$24.48
MARKET CAP 
4.332 M
YIELD 
N/A
SHARES OUTSTANDING 
23.037 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-30-2025
BETA 
-3.31
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$144,617
AVERAGE 30 VOLUME 
$57,842
Company detail
CEO: Lori Bisson
Region: US
Website: autonomix.com
Employees: 0
IPO year: 2024
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

We are a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Our principal executive offices are located at 21 Waterway Avenue, Suite 300, The Woodlands, TX.

Recent news

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

THE WOODLANDS, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof-of-concept study results will be featured in a poster presentation as part of PCR Innovators Day at the world-leading course in interventional cardiovascular medicine, EuroPCR, being held May 20-23, 2025 in Paris, France. Details of the poster p

Read more

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed a

Read more

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has engaged U.S. and international-based medical experts in interventional radiology and ca

Read more